13.35
price down icon1.04%   -0.14
after-market アフターアワーズ: 13.35
loading
前日終値:
$13.49
開ける:
$13.5
24時間の取引高:
392.89K
Relative Volume:
0.42
時価総額:
$558.46M
収益:
-
当期純損益:
$-168.05M
株価収益率:
-2.6023
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
-2.98%
1か月 パフォーマンス:
-5.65%
6か月 パフォーマンス:
-15.67%
1年 パフォーマンス:
-70.79%
1日の値動き範囲:
Value
$13.25
$13.59
1週間の範囲:
Value
$13.25
$13.99
52週間の値動き範囲:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
名前
Keros Therapeutics Inc
Name
セクター
Healthcare (1173)
Name
電話
617-314-6297
Name
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
職員
163
Name
Twitter
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
KROS's Discussions on Twitter

KROS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
13.35 558.46M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-10 ダウングレード BofA Securities Buy → Neutral
2025-01-21 ダウングレード Cantor Fitzgerald Overweight → Neutral
2025-01-17 ダウングレード Wedbush Outperform → Neutral
2024-12-16 ダウングレード Guggenheim Buy → Neutral
2024-12-16 繰り返されました Oppenheimer Outperform
2024-12-13 繰り返されました H.C. Wainwright Buy
2024-12-12 ダウングレード BTIG Research Buy → Neutral
2024-12-12 ダウングレード TD Cowen Buy → Hold
2024-12-12 ダウングレード William Blair Outperform → Mkt Perform
2024-11-05 開始されました Jefferies Buy
2024-10-24 開始されました Cantor Fitzgerald Overweight
2024-10-16 開始されました Scotiabank Sector Outperform
2024-09-23 開始されました Guggenheim Buy
2024-06-25 開始されました Oppenheimer Outperform
2024-02-21 開始されました William Blair Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-07-31 開始されました Wedbush Outperform
2023-07-26 開始されました BofA Securities Buy
2023-02-14 開始されました Cowen Outperform
2022-10-18 開始されました Truist Buy
2022-07-26 開始されました BTIG Research Buy
2020-12-08 繰り返されました H.C. Wainwright Buy
2020-05-04 開始されました H.C. Wainwright Buy
2020-05-04 開始されました Jefferies Buy
2020-05-04 開始されました Piper Sandler Overweight
2020-05-04 開始されました SVB Leerink Outperform
すべてを表示

Keros Therapeutics Inc (KROS) 最新ニュース

pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize

Jun 10, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 31, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus

May 30, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa

May 30, 2025

Keros Therapeutics Inc (KROS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Keros Therapeutics Inc (KROS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
Apr 04 '25
Option Exercise
0.30
49,367
14,810
302,223
GORDON CARL L
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
ORBIMED ADVISORS LLC
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
大文字化:     |  ボリューム (24 時間):